Wendall Wierenga Cytokinetics Inc (CYTK) insider trading activity

Wendall Wierenga is Director of CYTOKINETICS INC. Currently has a direct ownership of 24,686 shares of CYTK, which is worth approximately $1.16 Million. The most recent transaction as insider was on Jul 01, 2022, when has been sold 137 shares (Common Stock) at a price of $41.0 per share, resulting in proceeds of $5,617. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 24.7K

0.52% 3M change

31.82% 12M change

Total Value Held $1.16 Million

WENDALL WIERENGA Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 01 2022	BUY Grant, award, or other acquisition	$5,617 $41.0 p/Share	137 Added 1.11%	12,170 Common Stock
May 10 2022	BUY Grant, award, or other acquisition	-	5,000 Added 29.35%	12,033 Common Stock
Apr 01 2022	BUY Grant, award, or other acquisition	$5,603 $38.38 p/Share	146 Added 2.03%	7,033 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	$5,612 $46.0 p/Share	122 Added 1.74%	6,887 Common Stock
Dec 27 2021	SELL Open market or private sale	$184,845 $44.37 p/Share	4,166 Reduced 38.11%	6,765 Common Stock
Dec 27 2021	BUY Exercise of conversion of derivative security	$22,746 $5.46 p/Share	4,166 Added 27.59%	10,931 Common Stock
Oct 01 2021	BUY Grant, award, or other acquisition	$11,242 $36.74 p/Share	306 Added 4.33%	6,765 Common Stock
Jul 07 2021	BUY Grant, award, or other acquisition	$1,246 $19.77 p/Share	63 Added 0.97%	6,459 Common Stock
Jul 01 2021	BUY Grant, award, or other acquisition	$9,986 $20.98 p/Share	476 Added 6.93%	6,396 Common Stock
May 12 2021	BUY Grant, award, or other acquisition	-	5,000 Added 45.79%	5,920 Common Stock
Apr 01 2021	BUY Grant, award, or other acquisition	$9,996 $24.44 p/Share	409 Added 30.78%	920 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	$9,995 $19.56 p/Share	511 Added 50.0%	511 Common Stock

Also insider at

CRNX

Crinetics Pharmaceuticals, Inc. Healthcare